Background: Mastectomy flap necrosis is a common complication of immediate breast reconstruction that impacts recovery time and reconstructive success. Nitroglycerin ointment is a topical vasodilator that has shown to improve skin flap survival in animal models. The objective of this study was to evaluate if the application of nitroglycerin ointment to the breast skin after mastectomy and immediate reconstruction causes a decrease in the rate of mastectomy flap necrosis compared to placebo. 
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Introduction
Background
The blood supply to the breast skin comes from the underlying breast gland and from the dermal and sub-dermal plexuses of the skin. 1 During mastectomy, the blood supply to the skin is compromised which may lead to areas of superficial or full thickness mastectomy flap necrosis (Figure 1 ). These areas become obvious in the first post-operative week and can lead to prolonged recovery, delay in adjuvant treatments and an unsatisfactory reconstructive outcome.
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Mastectomy flap necrosis is a frequent complication occurring in 18-30% of patients undergoing mastectomy and immediate reconstruction. [2] [3] [4] [5] The incidence of this complication has increased as the rate of nipple-sparing mastectomies and direct-toimplant reconstructions have increased. [6] [7] [8] Other risk factors for developing this complication are well described and include: increasing age (>65 years old), obesity (BMI >30), large breast size (mastectomy weight >800grams), wise-pattern incision, previous radiation and active smoking. [9] [10] [11] [12] [13] Prevention of mastectomy flap necrosis is dependent on the surgeon's intra-operative clinical judgment as he/she evaluates mastectomy skin that needs to be excised. Recently, laser assisted indocyanine green dye angiography (SPY Elite) is an intraoperative tool which may help determine areas of decreased perfusion thereby allowing the surgeon to excise these more accurately. 14 Although SPY elite has been shown to be highly sensitive and specific, it is an expensive tool not readily available outside of large centers.
recent cost analysis showed that the use of SPY for prevention of mastectomy flap necrosis is only cost effective if used in high-risk patients (BMI>30, smokers, mastectomy weight >800grams). 16 An ideal preventative measure for mastectomy flap necrosis would be simple, cheap and easy to administer.
Nitroglycerin ointment is a potent topical vasodilator that increases local blood flow to the skin by dilating both arteries and veins. 17 It has been shown to enhance skin flap survival in an animal model following frequent application of 2% nitroglycerin ointment. 18 First described for the management of angina pectoris, nitroglycerin ointment is currently being used to aid in the healing of anal fissures, pressure sores and peripheral tissue ischemia in neonates. 17, [19] [20] [21] [22] 24 Despite this evidence, nitroglycerin ointment is not currently being used to prevent mastectomy flap necrosis and there are no studies evaluating the effect of nitroglycerin ointment on mastectomy flap necrosis rates in patients undergoing mastectomy with immediate reconstruction.
Study Objective
The primary objective of this study was to evaluate if a single post-operative application of nitroglycerin ointment (Nitro-Bid 2%, 45mg) decreases the rate of mastectomy flap necrosis in patients undergoing mastectomy with immediate breast reconstruction compared to patients receiving placebo. Secondary objectives included evaluating the effect of nitroglycerin ointment on the treatment received for mastectomy flap necrosis (dressings and/or debridement and closure) as well as on early complications such as seroma, hematoma, infection, explantation and capsular contracture.
Methods
Patient Trial Eligibility
The alteplase, aspirin, beta-blocker, calcium channel blocker, diuretics or thiazides). 25 
Sample Size Calculation
We reviewed the mastectomy flap necrosis rate at our institution for the years 2008 to 2011, which varied from 10.5% to 38.3%. Assuming a 20% rate for the placebo group, and considering a clinically significant rate reduction of 50%, a sample size of 200 patients per arm for a total of 400 patients was calculated (α=0.05, 2-sided; β=0.20). A single interim efficacy analysis was planned after 50% of patients had been accrued. A Peto-Haybittle stopping boundary (P < 0.001) was to be employed.
Data Collection
Pre-operative, operative and post-operative case report forms (CRF) were created for the purpose of prospective data collection and were completed by the surgeon. The following information was collected on the pre-operative CRF (Appendix A): date of birth, body mass index, smoking status, pathology, history of biopsy or lumpectomy, radiation exposure, chemotherapy exposure, hormonal treatment, medical comorbidities; breast measurements including bra size, breast ptosis and previous scars. or flap necrosis (incisional further than 2mm and all other breast skin areas). Surgeons were asked to classify the necrosis as superficial (epidermolysis) or full thickness (into the dermis). Breast diagrams were provided for surgeons to note the area and size of necrosis.
Randomization and Ointment Application
A senior statistician at the Clinical Centre of Epidemiology and Evaluation at the At the time of surgery, the research coordinator consulted the randomization list for the next treatment allocation and delivered the study drug to the operating room.
Mastectomy was performed by a member of the University of British Columbia General 
Interim Analysis
On February 24 th 2014, after 165 patients had been randomized, the interim analysis was conducted. All randomized patients were included in the analysis in the group to which they were allocated (intention-to-treat). The interim report was sent to two independent plastic surgeons outside our institution for independent review. Based the findings of the interim report, the study was stopped early for proof of efficacy.
Statistical Analysis
To describe the patient population, descriptive statistics were generated for baseline variables by treatment group. Continuous variables were summarized with mean (SD) or median (10 th , 90 th percentiles) if the data were skewed. Categorical variables were summarized with frequency (percent). Pearson's chi-square test was used for betweengroup comparisons of proportions. Point and interval estimates were calculated for between-group differences. We also performed a secondary analysis adjusting for known risk factors for mastectomy flap necrosis. These factors were determined a priori based on literature review and surgeon experience and included: Age >65, body mass index > 30, active smoking, history of pre-operative radiation, mastectomy weight >800grams, wise-pattern incision, nipple sparing mastectomy and direct-to-implant reconstruction.
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We also did an exploratory analysis of whether the effect of nitroglycerin varied according to the number of risk factors. A score of one was given for each of the aforementioned risk factors. A total risk score was calculated as the sum of the eight scores. All analyses were performed using Stata 11.0 (StataCorp LP, College Station, TX) and all tests are two-sided.
Results
One hundred and sixty-five patients participated in the study, with 85 randomized to the nitroglycerin ointment arm and 80 to the placebo arm. Of the 85 patients in the treatment arm, one patient did not receive the allocated ointment and two patients had the ointment wiped off in the recovery room without un-blinding due to hypotension. There were no patients lost to follow-up and all randomized patients were included in their allocated group ( Figure 3-CONSORT diagram) .
Patient demographics and baseline characteristics were similar between the treatment and placebo group (Table 1) as were breast baseline characteristics (Table 2 ) and operative characteristics ( Table 4 ).
The difference in mastectomy flap incidence between the treatment and placebo groups was 18.5% (95% CI of 5.3% to 31%). The effect was consistent across severity of necrosis. The difference in the rate of necrosis was reflected in decreased rates of debridement and closure of the wound ( ). An exploratory analysis looking at the effect of nitroglycerin ointment on different risk factor groups was also performed ( Table 5 ). The total risk factor score ranged from 0 to 4. Due to small numbers we combined the 3 and 4 categories. As expected, the risk of MFN in the placebo group increased with increasing score. The observed risk of MFN was lower in the nitroglycerin group in all risk categories.
Early complications such as seroma, hematoma, infection and early capsular contracture occurred in 25.5% (42/165) of patients and were similar in both groups ( Table 6 ). The most common early complication was seroma which occurred in 12.7% (21/165) of patients. Severe headache was reported in 2.4% (2/85) of patients receiving nitroglycerin ointment compared to 0% in the placebo group. Hypotension was reported in two patients who received the nitroglycerin ointment. In both cases, the hypotension did not resolve with removal of the study ointment and was likely due to other factors.
The results of the interim analysis did not meet the pre-specified stopping boundary (i.e. p ≤ 0.001). However, given the large reduction in the rate of mastectomy flap necrosis in the nitroglycerin group the investigators were no longer in the state of personal equipoise and felt it unethical to continue to randomize patients. A conditional power calculation was performed; the probability of detecting a significant benefit for nitroglycerin should
Discussion
To our knowledge, this is the first randomized trial evaluating the use of nitroglycerin ointment in the prevention of mastectomy flap necrosis in patients undergoing mastectomy and immediate reconstruction. Our study demonstrated that the application of a single 45mg dose of nitroglycerin ointment at the time of the surgical dressing reduced the incidence of mastectomy flap necrosis by more than half. The absolute risk reduction of 18.5% translates to a number needed to treat of 5.4. In patients treated with nitroglycerin ointment we also found an approximate 50% reduction in full thickness mastectomy flap necrosis, which translates to a similar reduction in cases requiring surgical debridement and closure. In addition, after stratifying patients into risk factor subgroups, the observed reduction in MFN prevailed in all risk categories in patients treated with nitroglycerin. Given the small number of patients and events in each subgroup we were unable to determine definitively if the treatment effect might increase (or decrease) with increasing risk factors. Overall, these findings suggest that nitroglycerin ointment increases perfusion to the traumatized skin flap thereby reducing the occurrence of flap necrosis in this patient population.
The mechanism of action of topical nitroglycerin occurs through smooth muscle relaxation in the vessel wall thereby promoting both a venous and arterial dilation. 17 Endothelial dependent vessel relaxation impairment is important to the development of skin flap necrosis, a process that may be mitigated by nitroglycerin or other nitric oxide donors. 26 Nitroglycerin may also induce endothelial cells to synthesize prostacyclin, a known vasodilator and inhibitor of platelet aggregation, which may contribute to flap survival by decreasing thrombosis of smaller vessels. 27 Nitroglycerin ointment was first studied in an animal model by Rohrich et al. in 1984 and was found to significantly increase axial pattern skin flap survival in both rats (89.4% vs.
68.9% flap area survival) and pigs (74.1% vs. 50.5% flap area survival) when a 30mg dose was applied preoperatively and every six hours for three days. 18 In 1985, Nichter et al. studied the effects of nitroglycerin transdermal pads on random pattern flaps in rats using a 5mg daily dose for two weeks. They did not show a difference in flap survival compared to control, but this may be due to the much smaller daily dose or the transdermal delivery used in their protocol. 28 Nitroglycerin ointment was first used on skin flaps in humans a year later in a trial on the penile flaps of children undergoing hypospadias repair and was found to improve flap survival. 29 Nitroglycerin ointment has also been studied in comparison to other vasodilating agents such as enteral phenoxybenzamine, enteral nifedipine as well as intravenous allopurinol and was found to be superior in treating failing random pattern skin flaps in rats. [30] [31] The most substantial animal study looking at the effect of nitroglycerin on random pattern skin flaps included 61 rats randomized to 1 of 6 topical treatment groups, treated immediately post-operatively and every 6 hours for a week. Although topical nitroglycerin alone improved flap survival, the combination of topical nitroglycerin and topical trolamine salicylate showed the greatest capacity for flap salvage. 32 Although the majority of animal studies have shown increased flap survival with the use of nitroglycerin ointment, three studies have shown a lack of benefit. 29, 33, 34 In all of these studies the dose of nitroglycerin used was low (5mg), which may be the reason a significant effect was not detected.
The doses used in previous clinical studies on nitroglycerin and mastectomy flaps ranged from a single 5mg application to a 50mg transdermal daily protocol for 5 days. [23] [24] The dose used in this study (45mg, 3 inches) was determined using these previous studies as a guideline as well as by consulting an academic cardiologist. We selected a single 45mg dose to keep the protocol simple yet effective and allow for patient monitoring in the case of adverse events. This dose was applied to a single breast and caution should be exercised in treating both breasts. Either doubling the dose or splitting the dose over a larger surface area may have greater effects on a patient's blood pressure.
In this study the overall incidence of mastectomy flap necrosis in the placebo group was higher than we had estimated (33.8%), but similar to rates in the literature. 35, 36 This rate is also consistent with the significant rise in mastectomy flap necrosis at our institution since the adoption of nipple-sparing mastectomy and direct-to-implant reconstruction.
Despite the higher risk of mastectomy flap necrosis, these newer techniques allow for better aesthetic outcomes often in a single stage and are therefore preferred by patients and surgeons.
The complications seen in this cohort were consistent with previous studies. 36, 37 There was a small decrease in overall complication rates in the treatment versus placebo group The strengths of this study include the randomized controlled-trial design; blinded ointment allocation, near perfect adherence to treatment allocation and the 100% followup rate. In addition, our findings are generalizable to most breast cancer patients although caution is advised in older patients and patients on anti-hypertension medication who may be more sensitive to nitrates. These patients were excluded from the study but have since been treated routinely with nitroglycerin ointment without any adverse events.
A limitation of this study is that it was conducted at a single center although three 
Conclusion
The single application of nitroglycerin ointment (45mg, 3 inches) to the breast skin in patients undergoing mastectomy with immediate reconstruction decreased the incidence of mastectomy flap necrosis by half (33.8 to 15.3%) with a number needed to treat of 5.4.
Nitroglycerin ointment application on mastectomy flaps is a simple, readily available and affordable ($3) measure to prevent mastectomy flap necrosis. In high-risk patients, it can be combined with other modalities to optimize patient outcomes. The authors propose that a simple and cost-effective approach to the prevention of mastectomy flap necrosis would include the application of nitroglycerin on all patients undergoing mastectomy with immediate reconstruction.
